Ovid Therapeutics Inc expected to post a loss of 16  cents a share - Earnings Preview

Ovid Therapeutics

11/03/2022 13:37

* Ovid Therapeutics Inc  OVID.OQ   OVID.O  is expected
to show a
fall in quarterly revenue when it reports  results on March 14
(estimated). 
    * ​Refinitiv's mean analyst estimate for Ovid Therapeutics
Inc is
for a loss of 16 cents per share. For the same quarter last
year, the company reported a loss of 34 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ovid
Therapeutics
Inc is $5.5​, above​ its last closing price of $3.49. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.18       -0.18      -0.17     Beat    7.5
 Jun. 30 2021  -0.15       -0.16      -0.23     Missed  -42
 Mar. 31 2021  1.39        1.68       2.53      Beat    50.8​
 Dec. 31 2020  -0.25       -0.31      -0.34     Missed  -9.7
 ​​Sep.        -0.34       -0.36      -0.28     Beat    22.6
 30 2020                                                
 Jun. 30 2020  -0.35       -0.36      -0.41     Missed  -15​
 Mar. 31 2020  -0.33       -0.33      -0.37     Missed  -11.6
 Dec. 31 2019  -0.37       -0.41      -0.35     Beat    14.4
 This summary was machine generated March 11 at 13:37 GMT.  All
figures in US dollars  unless otherwise stated